Dr Akshay Desai, of Harvard Medical School, reviews key studies in heart failure as presented at the European Society of Cardiology (ESC) Congress 2020, which was held as a virtual conference because of the coronavirus pandemic. He discusses significant new data from the EMPEROR-Reduced and DAPA-CKD studies regarding the value of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF), and in patients with chronic kidney disease, with or without diabetes.
He also reports on pivotal data from the EXPLORER-HCM trial, which examined a novel pharmacologic approach to management of obstructive hypertrophic cardiomyopathy.
Finally, Dr Desai discusses data on sacubitril/valsartan in heart failure with preserved ejection fraction (HFpEF) from the PARALLAX trial, as well as results from the BRACE-CORONA trial on the safety of renin-angiotensin system antagonists in patients with mild to moderate COVID-19.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author’s own